StockData

Arcus Biosciences vs Verastem

RCUS and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RCUS and VSTM compare

Arcus Biosciences is the larger company, worth 3.1 times as much as Verastem ($2.1B against $697M).

Verastem keeps more of each dollar of sales as profit, with a net margin of −232% compared with −393% at Arcus Biosciences.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRCUSVSTM
Size and price
Market cap$2.1B$697M
Share price$16.86$7.70
Change, 1 year−14.8%−5.1%
Change, 5 years−63.6%−76.1%
Beta (5Y)1.092.60
Employees601102
StockData Score
Total score33
Valuation score00
Growth score2 (better)1
Performance score01 (better)
Health score11
Dividend score00
Valuation
P/S18.3×8.0× (better)
P/B4.6× (better)14.0×
FCF yield−22.1%–
Fair value$7.35–
Margin of safety−129%–
Growth
Revenue growth (TTM)−55.3%–
Revenue growth, 5Y average25.9% (better)−19.0%
Profitability
Operating margin−415%−183% (better)
Net margin−393%−232% (better)
FCF margin−406%–
Return on equity−90.8% (better)−471%
Financial health
Interest coverage−44.2× (better)−108.3×
Current ratio3.82 (better)2.25
Altman Z-score−0.67 (better)−7.27
Piotroski F-score14 (better)
Dividends and buybacks
Buyback yield−13.4%–
Shareholder yield−13.4%0.00% (better)
Ownership
Held by institutions96.3%109%
Held by insiders31.7%1.8%
Insider net buying, 12 months−$9.3M−$816K (better)
Short interest, % of float15.2%22.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.